Singapore markets closed

BNTX Jan 2025 110.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
5.500.00 (0.00%)
As of 10:23AM EDT. Market open.
Full screen
Previous close5.50
Open5.50
Bid0.00
Ask0.00
Strike110.00
Expiry date2025-01-17
Day's range5.50 - 5.50
Contract rangeN/A
Volume2
Open interest320
  • Reuters

    UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year

    Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

  • Reuters

    BioNTech says 90% of 2024 revenues will accrue at end of year

    FRANKFURT (Reuters) -Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

  • GlobeNewswire

    BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

    Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soonPresented clinical data at the American Association for Cancer Research (“AACR”) Annual Meeting for individualized and off-the-shelf mRNA-based cancer vaccine